Skip to main content

Table 1 Baseline patient characteristics

From: Combination antibiotic therapy versus monotherapy in the treatment of acute exacerbations of chronic obstructive pulmonary disease: an open-label randomized trial

Characteristics Monotherapy (n = 79) Combination therapy (n = 60) P-value#
Age, years 71.4 ± 11.8 71.7 ± 12.1 0.89
Male sex, no. (%) 55 (69.6) 46 (76.7) 0.36
Smokers, no. (%) 43 (54.4) 34 (56.7) 0.79
Body mass index ± SD 24.1 ± 3.1 23.7 ± 2.6 0.25
VAS score 34.1 ± 11.1 32.3 ± 16.1 0.54
Percent predicted FEV1, %† 58.0 ± 14.8 55.8 ± 16.1 0.42
Percent predicted FVC, %† 71.3 ± 17.1 72.1 ± 18.2 0.47
Comorbidities, no. (%)
 Ischemic heart disease 31 (39.2) 27 (45.0) 0.52
 Heart failure 20 (25.3) 13 (21.7) 0.63
 Diabetes mellitus 11 (13.9) 10 (16.7) 0.46
 Lung cancer 2 (2.5) 6 (10.0) 0.21
WBC
1. > 10 × 109/L, no. (%) 42 (53.1) 34 (56.7) 0.52
 C-reactive protein (mg/L), median (IQR) 46.0 (12–124) 44.8 (18–113) 0.73
 PaO2 (mm Hg), median (IQRs) 71.7 (41–99) 72.8 (43–115) 0.72
 PaCO2 (mm Hg), median (IQRs) 42.8 (27–90) 40.9 (25–82) 0.45
 ICS, no. (%) 76 (96.2) 59 (98.3) 0.08
 SCS, course for current AECOPD, no. (%) 30 (37.9) 22 (36.7) 0.34
  1. AECOPD acute exacerbation of COPD, FEV1 postbronchodilator forced expiratory volume in 1 s, ICS inhalation corticosteroids, IQRs interquartile range, SCS systemic corticosteroids, SD standard deviation, WBC white blood cell
  2. #Fisher’s Exact Test for propotion comparison; Mann–Whitney test for comparing the means
  3. Last recorded postbronchodilator value in a stable state before admission
  4. *The body mass index is the weight in kilograms divided by the square of the height in meters
  5. Plus–minus values represent means ± SD